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Objective: ADAMTS5 (aggrecanase-2) has been demonstrated to be crucial in the development of oste-
oarthritis (OA), by use of several mouse mutants carrying either truncated, catalytically inactive enzymes
or aggrecanase-resistant mutant aggrecan. We have selected recombinant monoclonal antibodies
directed against ADAMTS5, by using Intracellular Antibody Capture Technology (IACT). CRB0017 revealed
very high afﬁnity for the enzyme in Biacore analyses and very good speciﬁcity in a panel of binding
assays. Therefore, we tested CRB0017 in a relevant spontaneous OA model, the STR/ort mouse.
Design: STR/ort male mice were recruited at 5 months of age, and treated intra-articularly in each knee
with CRB0017 1.2 mg, CRB0017 12 mg, or vehicle. After 6 weeks, the intra-articular administration of
CRB0017 was repeated with the same doses. After 3 months from recruitment, the animals were
sacriﬁced and the femorotibial joints processed for histology and scored in a blind fashion according to
both Mankin’s and the OARSI methods.
Results and conclusions: All histological scores were signiﬁcantly decreased in the CRB0017 12 mg/knee
group compared to vehicle, while administration of CRB0017 1.2 mg was associated with a trend to a
decrease in the same parameters. Therefore, CRB0017 administered twice in 3 months could modify the
course of OA in the STR/ort mouse, by delaying cartilage breakdown as assessed histologically. The
procedure of blind scoring of the histological samples clearly showed that knee intra-articular admin-
istration of CRB0017, an anti-ADAMTS5 antibody, dose-dependently improved disease progression in a
relevant animal model of OA.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The etiology of osteoarthritis (OA), the most widespread form of
arthritis, is largely unknown. Breakdown of aggrecan, the most
represented non-collagenous protein in articular cartilage, is an
early event in the onset and progression of OA, and therefore since
their discovery aggrecanases have been postulated to have a role in
OA, which has been recently widely demonstrated in relevant an-
imal models. Mouse mutants lacking functional ADAMTS5R. Chiusaroli, Department of
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s Research Society International. P(aggrecanase-2) are protected from articular cartilage loss in a
relevant OA surgical paradigm1, as are mice carrying aggrecanase-
resistant mutant aggrecan2. As a consequence, ADAMTS5 has
since been regarded as an appealing possible therapeutic target for
OA3.
In order to evaluate a possible therapeutic approach to OA via
biologic interference with ADAMTS5, we have used the proprietary
Intracellular Antibody Capture Technology (IACT) to select a panel
of antibody domains from large recombinant scFv SPLINT li-
braries4e6. The antibodies were selected using different and spe-
ciﬁcally engineered domains of ADAMTS5 as antigens.
In particular, mAb CRB00177 demonstrated very high afﬁnity for
the spacer domain of the enzyme (as revealed by Biacore assays)
both in the single chain and in the IgG4 format. Moreover, the
antibody was shown to reduce the proteolytic activity of the
enzyme in vitrowith an IC50 in the low nanomolar range. Therefore,ublished by Elsevier Ltd. All rights reserved.
Fig. 1. Representative histology images of knee joints from 8-mo STR/ort mice treated
with CRB0017 12 mg/knee (b) or vehicle (a) for 3 months. Bar, 0.2 mm.
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the hypothesis that interfering with the biological activity of
ADAMTS5 could improve the course of OA, we testedmAb CRB0017
in STR/ort mice, which develop a spontaneous, age-related OA and
are considered a relevant model for human OA8e11.
Methods
mAb CRB0017 production and puriﬁcation
Anti-ADAMTS5 CRB0017 scFv was reformatted to IgG4 antibody
for expression in mammalian cells. CHO-S cells were stably trans-
fected with plasmids encoding CRB0017 heavy and light chains.
Clariﬁed supernatant was loaded onto HiTrap protein A-sepharose
column (GE Healthcare) previously equilibrated with PBS. The
antibody was recovered by acidic elution (10 mM HCl pH 2.5) fol-
lowed by immediate neutralization with 1 M TriseHCl pH 8.5.
Pooled fractions were dialyzed against PBS.
Animal model
Male STR/ort mice (Harlan, Italy) were housed with ad libitum
access to food and water, in a temperature-controlled room with a
12 h light/dark cycle. All the experimental procedures described
were in compliance with international laws and policies (Directive
2010/63/EU revising Directive 86/609/EEC on the protection of
animals used for scientiﬁc purposes; Guide for the Care and Use of
Laboratory Animals, U.S. National Research Council, 1996).
STR/ort mice were recruited at 5 months of age (n ¼ 20e22/
treatment group), randomly distributed by treatment in each cage,
with four animals per cage, weighed and treated intra-articularly,
each in both knees with single dosing of either CRB0017 1.2 mg,
CRB0017 12 mg, or vehicle (in a ﬁnal volume of 4 ml). The control
group consisted only of vehicle treated mice as we never observed
any signiﬁcant differences between mice treated with an irrelevant
IgG4 and vehicle treatedmice in our previous experiments (data not
shown). After 6weeks the intra-articular administration of CRB0017
was repeatedwith the same doses. After 3months from recruitment
the animals were sacriﬁced and hind limbs explanted and ﬁxed in
formalin o/n. Knees were embedded in parafﬁn, 4-micron thick
sections were produced and stained with toluidine blue and then
scored in a blind fashion according to both Mankin’s and the OARSI
scores12,13. Total score represents the OARSI score plus cell loss plus
GAG loss scores. This takes into account all parameters that were
reported separately in order to provide the best detail, allowing a
further and more complete view on OA progression as a whole.
Since OA develops independently in each joint of each single
STR/ort mouse8e11, both knees were injected. Accordingly, the
joints were scored independently for each animal. To support this
approach, during the setup phase of the analysis model, we
investigated the presence of a correlation between the right and
left knee scores in control groups of mice treated either with
vehicle or with an irrelevant human IgG4 in three different ex-
periments (including the control group of the present study, in total
75 mice). This analysis showed that the correlation between the
pathology scores evaluated in right and left knees is very low, if any,
and never statistically signiﬁcant, in spite of the large number of
animals involved (data not shown). Statistical analysis was per-
formed by KruskaleWallis ANOVA on ranks followed by Dunn’s test
comparing each treatment group vs vehicle.
Results
As we aimed for a therapeutic protocol, and not a preventive
one, 5-month-old male STR/ort mice were enrolled for thisexperiment. At this age, 100% of male STR/ort mice display some
degree of OA. Mice were monitored daily for the duration of the
experiment, and showed general well being; no deaths or weight
loss were observed, nor other relevant signs of toxicity. Three
months after the ﬁrst injection, vehicle treated mice displayed se-
vere OA with clefting, ﬁbrillation and erosion of articular cartilage,
sclerosis and focally necrosis of subchondral bone, osteochon-
drophytes and pathological changes in ligaments and capsula
[Fig. 1(a)].
All OA histopathological scores were dose-dependently reduced
following treatment with CRB0017, with the higher dose reaching a
profound, statistically signiﬁcant decrease vs vehicle, for all pa-
rameters [Fig.1(b) and 2]. This experiment was repeated twice with
the same protocol, yielding the same results (data not shown).Discussion
Since the discovery of its importance in OA onset and progres-
sion, ADAMTS5 has been pursued as a target for therapies aimed at
disease modiﬁcation, with strategies employing design of small
molecules to inhibit its protease activity3,14. Unfortunately this
search has been rewarded with little success, likely because of the
high homology of the catalytic domain across the diverse metal-
loprotease families, and the resulting difﬁculties at achieving
speciﬁcity in order to avoid a burden of undesired effects. With the
aim of developing a therapeutic approach to OA devoid of off-target
side effects, we attempted to interfere with ADAMTS5’s function by
Fig. 2. Histopathological OA scoring of tibial medial plateaus from 8-mo STR/ort mice treated with CRB0017 12 mg/knee (n ¼ 20, n. of knees ¼ 34) or CRB0017 1.2 mg/knee (n ¼ 21, n.
of knees ¼ 37) or vehicle (n ¼ 20, n. of knees ¼ 34) for 3 months, according to both the OARSI and Mankin’s methods. Grade: scale 0e6. Stage: scale 0e4. Cell loss: scale 0e3. GAG
loss: scale 0e4. Total score represents the OARSI score plus cell loss plus GAG loss scores. Statistics were performed by KruskaleWallis ANOVA on ranks followed by Dunn’s test
comparing all treatment groups vs vehicle. Box plots represent median and 5% and 95% conﬁdence limits; bars are the most distant values from the median that are not outliers,
while dots are the outliers.
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selective screening of recombinant scFv libraries to isolate speciﬁc
antibodies directed against single domains of ADAMTS5. The best
candidate for therapeutic development was mAb CRB0017, which
demonstrated excellent afﬁnity (KD in low nanomolar range), and
high selectivity for its antigen7. A previous study has highlighted
the possibility of targeting ADAMTS5’s exosites in its ancillary
domain as a possible therapeutic strategy to reduce its activity15. In
order to obtain a proof of concept for this approach, we studied the
effects of CRB0017 in our animal model of choice for OA, the STR/ort
mouse. We selected intra-articular administration in view of its
compliance in osteoarthritic patients for a treatment that is
assumed to be once in several weeks, and arguably should reduce
the risk of side effects in virtue of the low amount of compound
used.
As a possible limitation of the STR/ort model it is to be
acknowledged that in mice at 5 months of age (i.e., at the beginning
of the follow-up) it is not possible to have a baseline observation
nor to select a signal joint (i.e., the worst joint) that could be fol-
lowed during the pathology progression, as usually done in human
studies. Nevertheless, as above detailed, we demonstrated the
absence of any statistically signiﬁcant correlation between the
pathology scores evaluated in right and left knees in control ani-
mals treated with vehicle or with an irrelevant human IgG4. On
these bases, we believe that in these speciﬁc experimental condi-
tions considering each joint as independent does not bias the val-
idity of the results. Therefore, both knees were injected, and scored
independently for each animal.
Another possible limitation of the study is that it is not possible
to determine how much of the activity observed can be due to the
local activity of CRB0017 injected or to a systemic activity of the
mAb that possibly leaks from the synovial space, since no quanti-
tative bioanalytical methods were applied to detect the circulating
CRB0017. Although, due to the high local concentration of mAb, theformer hypothesis seems more probable, this issue will be
addressed in further studies in which the effect of a systemic
administration will be compared to that of an intra-articular in-
jection with the same dose level, in addition assessing the mAb
circulating levels with a properly validated method.
In conclusion, mAb CRB0017 administered twice in 3 months
indeedmodiﬁed the course of OA in the STR/ort mouse, by delaying
cartilage breakdown as assessed histologically. The procedure of
blind scoring of the histological samples clearly showed a dose
dependent effect of the antibody in reducing the severity of the
osteoarthritic pathology in the STR/ort mice. Taken together, these
data show that knee intra-articular administration of mAb
CRB0017, an anti-ADAMTS5 monoclonal antibody targeting an
ancillary domain, dose-dependently improved disease progression
in a relevant animal model of OA. To the best of our knowledge, this
is the ﬁrst report on the efﬁcacy of a recombinant mAb against
ADAMTS5 in OA disease modiﬁcation; we believe that the data here
presented suggest a possible novel therapeutic approach for OA.
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